PRESENTATION ON BRAND INDIA PROMOTION - PowerPoint PPT Presentation

About This Presentation
Title:

PRESENTATION ON BRAND INDIA PROMOTION

Description:

PRESENTATION ON BRAND INDIA PROMOTION By Ashutosh Gupta COA Member -Pharmexcil Executive Director -Medicamen Biotech Ltd. Email : guptaashutosh_at_medicamen.com – PowerPoint PPT presentation

Number of Views:108
Avg rating:3.0/5.0
Slides: 17
Provided by: phar97
Category:

less

Transcript and Presenter's Notes

Title: PRESENTATION ON BRAND INDIA PROMOTION


1
  • PRESENTATION ON BRAND INDIA PROMOTION

By Ashutosh Gupta COA
Member -Pharmexcil Executive Director
-Medicamen Biotech Ltd. Email
guptaashutosh_at_medicamen.com
2
INTRODUCTION TO SMES
  • Gross Capital Below 5 Crores.
  • 2. Top Management comprises of 2-3 individuals in
    most cases.
  • 3.Limited resources.
  • 4.Lack of protection and minimal chances of
    Bailout.
  • 5.Good source for employment.
  • 6.Lack of automation.
  • 7.Generic Sales / Lack of profitability.

3
IMPORTANCE OF BRAND INDIA
1.Goes a long way to help SMES for better
exports. 2. Better acceptability of Products
Companies. 3. Better Margins. 4. Better Brand
Positioning w.r.t. CHINA. 5.More investments and
JVS. 6.Big opportunity awaiting in 2012 in terms
of patents expiring.
4
BRAND INDIA PROMOTION
  • Special programes to upgrade the industry image
    abroad as well as inside the country.
  • Pharmacopeal leverage.
  • Indias own Pharma expo in India as well as
    abroad.
  • Cooperative agreements with FDAs.
  • Provision of easy finance.
  • Incentive to SMEs for entry into regulated
    markets.
  • Task should be shared with indians abroad.
  • Need for comprehensive package for the industry.

5
  • SPECIAL PROGRAMMES TO
  • UPGRADE THE INDUSTRY IMAGE
  • Trust building of our Government towards our
    Industry.
  • Road shows abroad.
  • Specific Ministerial delegations.
  • Special diplomatic task force.
  • Designated technical official in important
    markets in embassies.

6
2. PHARMACOPEAL LEVERAGE
  • IP is today at par with BP.
  • COPPs
  • Brand image of Pharmacopia.
  • Leap jump ahead of china.
  • Cost effectiveness.
  • Better Documentation.
  • Better Product Range.

7
3. INDIAS OWN PHARMA EXPO
  • Show of strength.
  • We will come at par with other industries.
  • We reach all parts of the world.
  • Better exposure.
  • International Participations.

8
4. COOPERATIVE AGREEMENTS with FDAs
  • Better Brand image.
  • Time saving.
  • Cost effective
  • Makes way for FDIS and JVS.
  • Pharmacopeal leverage.
  • Increase in exports.

9
5 PROVISION OF EASY FINANCE
  • SMES always struggle due to lack of finance.
  • If finance is available more exports can be
    attained.
  • Easy upgradation towards CGMP/GLP.
  • Concentrated effort on exports.
  • Brand building of products.
  • Better image of Indian industry.

10
6. INCENTIVES TO SMES FOR ENTRY INTO REGULATED
MARKETS
  • Huge finance required.
  • Bioequivalence
  • Validations.
  • CTD Dossiers.
  • Trained regualatory staff.
  • Huge gestation period.
  • Scope of profitability.
  • Better number in US and EUROPE.
  • Jump in exports.
  • Better brand image.
  • Long lasting effects.

11
7.TASK SHOULD BESHARED WITH INDIANS ABROAD
  • Enrolment as associate members.
  • Most of Indians are well established .
  • They will feel more attatched.
  • Broad vision from the markets perspective.
  • First hand information.
  • Provides vast scope for improvement.
  • More Effective Buyer seller meet in India and
    abroad.
  • Better representation in terms of brand India.
  • We meet good buyers resulting in growth of
    exports.

12
8. COMPREHENSIVE PACKAGE
  • NEED
  • International conditions are very volatile.
  • Regulatory authorities becoming more stricter day
    by day.
  • More Documentations coming into view.
  • More infrastructural requirements.
  • India gaining image of Best source for low cost
    good quality generics.
  • Yearly updations becoming indispensable.
  • Opportunities awaiting us.

13
CHALLENGES TODAY
  • COPPS
  • Bioequivalence studies.
  • Investments required in validations.
  • Yearly updations.
  • GLP
  • Automation
  • Dying API industry.
  • Brand development.
  • Gestation period between application of dossiers
    and commercial order.

14
SUGGESTIONS
  • 1.Reimbursement of bioequivalence cost atleast
    50.
  • 2. Subsidy to units for upgradation from schedule
    M to CGMP.
  • 3.Easy finance for upgradation.
  • 4. Cluster development instead of SEZS.
  • 5. Increase in incentives.
  • 6. Subsidised API units.
  • 7.More research centres like NIPER.
  • 8.GLP upgradation subsidy.
  • 9. Automation subsidy.
  • 10. Marketing coops abroad should be promoted.

15
LET THE VOICE BEGIN
16
Thank You!
Write a Comment
User Comments (0)
About PowerShow.com